Eli Lilly’s Mounjaro™ (tirzepatide) has received FDA approval for use alongside diet and exercise to improve blood sugar control in adults who have type 2 diabetes.

• A first-in-class treatment, Mounjaro activates the GLP-1 and GIP receptors in the body to improve blood sugar control.
• The recommended starting dose is 2.5mg administered via subcutaneous injection once weekly, with the dose increased to 5mg once weekly after four weeks. If additional glycemic control is required after another four weeks, the dosage can be increased in increments of 2.5mg, up to a maximum of 15mg once weekly.
• Mounjaro has launched at a wholesale acquisition cost (WAC) of $974.33 per month.